Finally, there may be some relevance to ICI timing, as a recent small trial demonstrated improved survival in GBM with treatment with the anti-PD-1 antibody, pembrolizumab, prior to surgery, suggesting possible utility to immune system priming prior to antigen exposure during surgery [111•]. Here, PDCD1 is linked to glioblastoma.